Tiotropium/Salmeterol Inhalation Powder in COPD

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index (BDI)/Transition Dyspnoea Index (TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations

Key facts

Study ID

NCT00668772

Run by

Boehringer Ingelheim

People needed

207

Starts

2008-04-15

Expected to finish

2008-11-21

Last updated by the study team

2026-07-16

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Main:
• Diagnosis of chronic obstructive pulmonary disease (COPD)
• Post-bronchodilator forced expiratory volume in one second (FEV1) <80% predicted and FEV1/forced vital capacity (FVC) <70% predicted

You may not qualify if…

• Main:
• Significant other diseases then COPD
• Recent myocardial infarction (MI)
• Any unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year
• Hospitalisation for cardiac failure during the past year
• History of asthma

Where it is running

• 1184.15.01071 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
• 1184.15.01054 Boehringer Ingelheim Investigational Site — Clearwater, Florida, United States
• 1184.15.01063 Boehringer Ingelheim Investigational Site — Tampa, Florida, United States
• 1184.15.01064 Boehringer Ingelheim Investigational Site — Tampa, Florida, United States
• 1184.15.01065 Boehringer Ingelheim Investigational Site — Savannah, Georgia, United States
• 1184.15.01052 Boehringer Ingelheim Investigational Site — New Orleans, Louisiana, United States
• 1184.15.01055 Boehringer Ingelheim Investigational Site — St Louis, Missouri, United States
• 1184.15.01058 Boehringer Ingelheim Investigational Site — St Louis, Missouri, United States
• 1184.15.01062 Boehringer Ingelheim Investigational Site — St Louis, Missouri, United States
• 1184.15.01072 Boehringer Ingelheim Investigational Site — Summit, New Jersey, United States
• 1184.15.01053 Boehringer Ingelheim Investigational Site — Albuquerque, New Mexico, United States
• 1184.15.01070 Boehringer Ingelheim Investigational Site — New York, New York, United States
• 1184.15.01057 Boehringer Ingelheim Investigational Site — Elizabeth City, North Carolina, United States
• 1184.15.01059 Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• 1184.15.01051 Boehringer Ingelheim Investigational Site — Morgantown, West Virginia, United States
• 1184.15.43052 Boehringer Ingelheim Investigational Site — Gänserndorf, Austria
• 1184.15.43053 Boehringer Ingelheim Investigational Site — Vienna, Austria
• 1184.15.02057 Boehringer Ingelheim Investigational Site — Vancouver, British Columbia, Canada
• 1184.15.02059 Boehringer Ingelheim Investigational Site — Vancouver, British Columbia, Canada
• 1184.15.02055 Boehringer Ingelheim Investigational Site — Hamilton, Ontario, Canada
• 1184.15.02058 Boehringer Ingelheim Investigational Site — Ottawa, Ontario, Canada
• 1184.15.02051 Boehringer Ingelheim Investigational Site — Scarborough Village, Ontario, Canada
• 1184.15.02053 Boehringer Ingelheim Investigational Site — Toronto, Ontario, Canada
• 1184.15.02060 Boehringer Ingelheim Investigational Site — Longueuil, Quebec, Canada
• 1184.15.01069 Boehringer Ingelheim Investigational Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.